Verrica Pharmaceuticals Secures $50 Million Financing to Advance Dermatology Pipeline and Eliminate Debt
核心洞察
Verrica Pharmaceuticals raised approximately $50 million through a private placement financing to retire debt and extend operations into mid-2027.
The company will use $35 million to fully repay OrbiMed (搜索) debt obligations, eliminating restrictive covenants and interest payments.
Financing enables advancement of VP-315 Phase 3 trials for basal cell carcinoma (搜索) and global Phase 3 program for common warts (搜索) starting before end of 2025.
Verrica Pharmaceuticals Inc. announced November 24, 2025, that it has secured approximately $50 million in gross proceeds through a private investment in public equity (PIPE) financing, providing the dermatology therapeutics company with an extended cash runway into mid-2027 while eliminating existing debt obligations.
The financing, anchored by Caligan Partners LP (搜索) and PBM Capital along with new and existing investors, is expected to close on November 25, 2025. Caligan Partners will be entitled to designate a new member to Verrica's Board of Directors as part of the agreement.
Strategic Debt Elimination and Operational Extension
Verrica plans to allocate $35.0 million of the net proceeds to fully repay outstanding obligations under its Credit Agreement with OrbiMed (搜索), completely eliminating the debt facility and associated restrictive covenants. The remaining funds will support working capital and general corporate purposes.
"The significant capital provided by this financing will solidify our balance sheet, completely eliminate our debt facility and the restrictive covenants associated therewith, and provide the Company with an extended expected cash runway into mid-2027," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica.
Combined with the company's existing cash balance of $21.1 million as of the third quarter end and accounts receivable, the financing positions Verrica to fund operations through mid-2027 without the burden of interest and principal payments.
Pipeline Advancement and Market Opportunities
The extended financial runway enables Verrica to advance multiple clinical programs representing what the company characterizes as billion-dollar market opportunities. The company plans to initiate its global Phase 3 clinical program for common warts (搜索), targeting first patient enrollment in the U.S. before the end of 2025.
"We have heard clear enthusiasm from clinicians about the potential impact of VP-315 on the treatment of basal cell carcinoma (搜索), and we are excited about starting our global Phase 3 clinical program in common warts (搜索)," Rieger stated.
VP-315 (ruxotemitide), licensed from Lytix Biopharma AS, is being developed for non-melanoma skin cancers (搜索) including basal cell carcinoma (搜索) and squamous cell carcinoma (搜索). The additional funding will support preparation activities for VP-315's Phase 3 clinical program while the company explores non-dilutive development and commercialization opportunities globally.
YCANTH Commercial Strategy
The financing supports Verrica's commercial strategy for YCANTH® (VP-102), the first and only FDA-approved healthcare professional-administered treatment for molluscum contagiosum (搜索). The highly contagious viral skin infection affects approximately 6 million people in the United States, primarily children, with patients two years of age and older eligible for treatment.
YCANTH is also in development for common warts (搜索), which Verrica describes as "the largest remaining unmet need in medical dermatology." The company will continue exploring commercialization opportunities for YCANTH outside the United States and Japan.
Financing Structure and Terms
Under the securities purchase agreements, Verrica is selling 6,499,826 shares of common stock and/or pre-funded warrants to purchase 5,305,164 shares, along with accompanying Series C Warrants to purchase 2,951,241 shares. The combined pricing is $4.24125 per share of common stock and accompanying Series C Warrant.
The Pre-Funded Warrants carry a per share exercise price of $0.0001 and will not expire until exercised in full. The Series C Warrants are immediately exercisable with a per share exercise price of $6.315 and will expire on the fifth anniversary of closing.
TD Cowen (搜索) is serving as the sole placement agent for the PIPE financing. The securities are being sold in a transaction not involving a public offering and have not been registered under the Securities Act of 1933.